Guided Therapeutics (GTHP) Long-Term Debt Issuances (2016 - 2025)

Guided Therapeutics' Long-Term Debt Issuances history spans 13 years, with the latest figure at -$303000.0 for Q4 2025.

  • On a quarterly basis, Long-Term Debt Issuances fell 27.85% to -$303000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $160000.0, a 113.33% increase, with the full-year FY2025 number at $160000.0, up 113.33% from a year prior.
  • Long-Term Debt Issuances hit -$303000.0 in Q4 2025 for Guided Therapeutics, down from $108000.0 in the prior quarter.
  • Over the last five years, Long-Term Debt Issuances for GTHP hit a ceiling of $1.4 million in Q3 2022 and a floor of -$1.4 million in Q4 2022.
  • Historically, Long-Term Debt Issuances has averaged $43900.0 across 4 years, with a median of $131000.0 in 2024.
  • Biggest five-year swings in Long-Term Debt Issuances: surged 584.31% in 2022 and later decreased 27.85% in 2025.
  • Tracing GTHP's Long-Term Debt Issuances over 4 years: stood at $204000.0 in 2021, then tumbled by 784.31% to -$1.4 million in 2022, then skyrocketed by 83.02% to -$237000.0 in 2024, then fell by 27.85% to -$303000.0 in 2025.
  • Business Quant data shows Long-Term Debt Issuances for GTHP at -$303000.0 in Q4 2025, $108000.0 in Q3 2025, and $150000.0 in Q2 2025.